The FDA made the right call : When a promising new diabetes drug, troglitzone, was associated with liver injuries in 150 patients and four deaths, many thought the appropriate response was obvious. Sure enough, on Dec.1, Britain's Glaxo Wellcome, distributor of troglitazone under the name Romozin, decided to pull the drug in Britain after consultation with its regulators.